From Discovery to Differentiation: A High-Throughput TCR Discovery Platform Powering Next-Generation bispecific Therapeutics
- Demonstrating large-scale T-cell receptor discovery capability using a proprietary platform that identified hundreds of thousands of TCRs recognising previously uncharacterised antigens
- Validating the discovery-to-development bispecific pipeline by advancing a therapeutic program based on a novel, internally identified target that is distinct from existing programs
- Extending the platform beyond oncology into autoimmune disease by applying the same discovery engine to identify bispecific targets across multiple therapeutic indications